Вивчення нефропротекторної ефективності ірбесартану у хворих із діабетичною нефропатією
DOI:
https://doi.org/10.24026/1818-1384.1(38).2012.81060Ключові слова:
diabetic nephropathy, irbesartan, treatmentАнотація
Renoprotective efficiency the angiotensin-receptor antagonist irbesartan (300 mg QID) in comparison with calcium chenell-blocker amlodipine (10 mg QID) in type 2 diabetic patients with nephropathy at microalbuminuric stage was investigated in open label study. Renal function was evaluated by determination renal functional reserve (RFR) with modified protein tolerance test with instantized milk protein. After 3 months of therapy in patients group received irbesartan (n=30) RFR significantly elevated on 490% (P<0,01), whereas in amlodipine group only non significant 3,6% elevation was observed (P>0,05). At the end of study was observed significantly decrease urine albumin excretion rate at 43% (P<0,05) in irbesartan group. Opposite, in amlodipine group revealed non significant elevation urine albumin excretion rate. Treatment with irbesartan accompanied significant positive alteration many metabolic parameters (glicated haemoglobin (HbA1c), triglycerides and high density lipoproteins). In addition, at the end of the study in irbesartan group, despite to a similar to amlodipine group blood pressure (BP) level decrease (office BP and defined in diurnal BP monitoring), positive influence on diurnal BP rhythm was determined. Thus, nephroprotective action of irbesartan depends not only from angiotensin receptors blockade, but also from many positive metabolic effects and influence on diurnal BP rhythm.
Посилання
Zimmet P., Alberti K.G., Shaw J. Global and societal implications of the diabetes epidemic // Nature. – 2001. – Vol. 414 – P. 782-787. https://doi.org/10.1038/414782a
Raptis A.E., Viberti G. Pathogenesis of diabetic nephropathy // Exp. Clin. Endocrinol. Diabetes. – 2001. – Vol. 109(2). – P. 424-437. https://doi.org/10.1055/s-2001-18600
Castellino P., Shohat J., DeFronzo R.A. Hyperfiltration and diabetic nephropathy: is it the beginning? Or is it the end? // Semin. Nephrol. – 1990. – Vol. 10(3). – P. 228-241.
Yilmaz M.I., Saglam M., Qureshi A.R. et al. Endothelial dysfunction in type-2 diabetics with early diabetic nephropathy is associated with low circulating adiponectin // Nephrol. Dial. Transplant. – 2008. – Vol. 23(5). – P. 1621-1627. https://doi.org/10.1093/ndt/gfm828
Seo J.Y., Park J., Yu M.R. et al. Positive feedback loop between plasminogen activator inhibitor-1 and transforming growth factor-beta1 during renal fibrosis in diabetes // Am. J. Nephrol. – 2009. – Vol. 30(6). – P. 481-490. https://doi.org/10.1159/000242477
Taslipinar A., Yaman H., Yilmaz M.I. et al. The relationship between inflammation, endothelial dysfunction and proteinuria in patients with diabetic nephropathy // Scand. J. Clin. Lab. Invest. – 2011. – Vol. 71(7). – P. 606-612. https://doi.org/10.3109/00365513.2011.598944
Dengel D.R., Glodberg A.P., Mayuga R.S. et al. Insulin resistance, elevated glomerular filtration fraction and renal injury // Hypertension. – 1996. – Vol. 28. – P. 127-132. https://doi.org/10.1161/01.hyp.28.1.127
Шестакова М. В., Кутырина И. В., Рагозин А. К. Роль сосудистого эндотелия в регуляции почечной гемодинамики // Тер. архив. – 1994. – 12. – С. 83-86.
Шестакова М. В., Неверов Н. И., Дедов И. В. Роль внутриклубочковой гипертензии и липидов в развитии диабетической нефропатии // Тер. архив. – 1993. – 16. – С. 61-65.
Mogensen C.E., Chachati A., Christensen C.K. et al. Microalbuminuria: An early marker of renal involvement in diabetes // Uremia Invest. – 1985. – Vol. 9. – P. 85-95. https://doi.org/10.3109/08860228509088195
Caramori M.L., Fioretto P., Mauer M. The need for early predictors of diabetic nephropathy risk: Is albumin excretion rate sufficient? // Diabetes. – 2000. – Vol. 49. – P. 1399-1408. https://doi.org/10.2337/diabetes.49.9.1399
Poggio E.D., Wang X., Greene T., Van Lente F., Hall P.M. Performance of the Modification of Diet in Renal Disease and Cockcroft-Gault equations in the estimation of GFR in health and in chronic kidney disease // J. Am. Soc. Nephrol. – 2005. – Vol. 16. – P. 459-466. https://doi.org/10.1681/asn.2004060447
Bosch J.P., Lauer A., Glabman S. Short-term protein loading in assessment of patients with renal disease // Am. J. Med. – 1984. – Vol. 77. – P. 873-879. https://doi.org/10.1016/0002-9343(84)90529-1
Bosch J.P., Lew S., Glabman S., Lauer A. Renal hemodynamic changes in humans: response to protein loading in normal and diseased kidneys / / Am. J. Med. – 1986. – Vol. 81. – P. 809-816. https://doi.org/10.1016/0002-9343(86)90350-5
Amiel C., Blanchet F., Friedlander G. et al. Renal functional reserve // Nephrol. Dial. Transplant. 1990. – Vol. 5. – P. 763-770. https://doi.org/10.1093/ndt/5.9.763
Хіміч А. В., Романів Л. В. До методики вивчення функціонального ниркового резерву у людини // Здобутки клінічної і експериментальної медицини. – 2008. – 12(9). – C. 153.
Арьев А. Л. Возможности использования субмаксимального нагрузочного теста для оценки функционального состояния почек в практике ВТЭ // Организационно-методические вопросы социально-трудовой реабилитации инвалидов. Сб. науч. тр. - Л. - 1987. – C. 45-50.
Гоженко А. И., Куксань Н. И., Гоженко Е. А. Методика определения почечного фукционального резерва у человека // Нефрология. – 2001. – 14. – С. 70-73.
Шестакова М. В., Дедов И. И., Мухин Н. А. и соавт. Восстановление резерва фильтрационной функции почек у больных сахарным диабетом при лечении каптоприлом // Тер. архив. – 1991. – 16. – C. 50-55.
Паливода С. Н., Черепок А. А., Кулинич Р. Л. Оценка функционального состояния почек как предиктора эффективности антигипертензивной терапии у больных с гипертонической болезнью // Укр. кардіол. журн. – 2005. – 13. – С. 90-95.
Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia: report of a WHO/IDF consultation. Geneva, World Health Org. – 2006. – 46 p.
KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease // Am. J. Kidney Dis. – 2007. – Vol. 49(2). – P. S1-S180. https://doi.org/10.1053/j.ajkd.2006.12.005
Лакин Г. Ф. Биометрия. М.: Высшая школа. – 1990. – 352 с.
Parving H.H., Lehnert H., Brochner-Mortensen J. et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes // N. Engl. J. Med. – 2001. – Vol. 345. – P. 870-878. https://doi.org/10.1056/nejmoa011489
Lewis E.J., Hunsicker L.G., Clarke W.R. et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes // N. Engl. J. Med. – 2001. – Vol. 345. – P. 851-860. https://doi.org/10.1056/nejmoa011303
Giorgino F., Laviola L., Cavallo Perin P. et al. Factors associated with progression to macroalbuminuria in microalbuminuric type 1 diabetic patients: The EURODIAB Prospective Complications Study // Diabetologia. – 2004. – Vol. 47. – P. 1020-1028. https://doi.org/10.1007/s00125-004-1413-8
Hovind P., Tarnow L., Parving H.H. Remission and regression of diabetic nephropathy // Curr. Hypertens. Rep. – 2004. – Vol. 6. – P. 377-382. https://doi.org/10.1007/s11906-004-0057-x
Chan A.Y.M., Cheng M.L.L., Keil L.C., Myers B.D. Functional response of healthy and diseased glomeruli to a large, protein-rich meal // J. Clin. Invest. – 1988. – Vol. 81. – P. 245-254. https://doi.org/10.1172/jci113302
Schupp M., Janke J., Clasen R. et al. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity // Circulation. – 2004. – Vol. 109. – P. 2054-2057. https://doi.org/10.1161/01.cir.0000127955.36250.65
Rangwala S.M., Lazar M.A. Peroxisome proliferator-activated receptor gamma in diabetes and metabolism // Trends Pharmacol. Sci. – 2004. – Vol. 25(6). – P. 331-336. https://doi.org/10.1016/s0165-6147(04)00115-4
Takano H., Komuro I. Roles of peroxisome proliferator-activated receptor gamma in cardiovascular disease // J. Diabetes Complicat. – 2002. – Vol. 16(1). – P. 108-114. https://doi.org/10.1016/s1056-8727(01)00203-3
Parhofer K.G., Muenzel F., Krekler M. Effect of the Angiotensin Receptor Blocker Irbesartan on Metabolic Parameters in Clinical Practice: the DO-IT Prospective Observational Study // Cardiovasc. Diabetol. – 2007. – Vol. 6(1). – P. 36. https://doi.org/10.1186/1475-2840-6-36
Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report // Circulation. – 2002. – Vol. 106(25). – P. 3143-3421.
Kintscher U., Bramlage P., Paar W.D. et al. Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14 200 patients // Cardiovasc. Diabetol. – 2007. – Vol. 6. – P. 12. https://doi.org/10.1186/1475-2840-6-12
Isomaa B., Almgren P., Tuomi T. et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome // Diabetes Care. – 2001. – Vol. 24. – P. 683-689. https://doi.org/10.2337/diacare.24.4.683
Grundy S.M., Cleeman J.I., Merz C.N. et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines // Circulation. – 2004. – Vol. 110. – P. 227-239. https://doi.org/10.1161/01.cir.0000133317.49796.0e
Schmieder R.E., Veelken R., Gatzka C.D. et al. Predictors for hypertensive nephropathy: results of a 6-year follow-up study in essential hypertension // J. Hypertens. – 1995. – Vol. 13(3). – P. 357-365. https://doi.org/10.1097/00004872-199503000-00012
Nakano S., Fukuda M., Hotta F. et al. Reversed Circadian Blood Pressure Rhythm Is Associated With Occurrences of Both Fatal and Nonfatal Vascular Events in NIDDM Subjects // Diabetes. – 1998. – Vol. 47. – P. 1501-1506. https://doi.org/10.2337/diabetes.47.9.1501
Nakano S., Ogihara M., Tamura C. et al. Reversed Circadian Blood Pressure Rhythm Independently Predicts Endstage Renal Failure in Non-Insulin-Dependent Diabetes Mellitus Subjects // Journal of Diabetes and Its Complications. – 1999. – Vol. 13. – P. 224-231. https://doi.org/10.1016/s1056-8727(99)00049-5
Inaba M., Negishi K., Takahashi M., et al. Increased night:day blood pressure ratio in microalbuminuric normotensive NIDDM subjects // Diabetes Res. Clin. Pract. – 1998. – Vol. 40(3). – P. 161-166. https://doi.org/10.1016/s0168-8227(98)00026-6
Staessen J.A., Fagard R., Thijs L. et al. for the Systolic Hypertension in Europe (Syst-Eur) Trial investigators. Randomised double-blind comparison of placebo and active treatment or older patients with isolated systolic hypertension // Lancet. – 1997. – Vol. 350. – P. 757-764. https://doi.org/10.1016/s0140-6736(97)05381-6
Czupryniak L., Wisniewska-Jaronsinska M., Drzewoski J. Trandolapril restores circadian blood pressure variation in normoalbuminuric normotensive Type 1 diabetic patients // J. Diabetes Complications. – 2001. – Vol. 15(2). – P. 75-79. https://doi.org/10.1016/s1056-8727(00)00130-6
##submission.downloads##
Опубліковано
Номер
Розділ
Ліцензія
Авторське право (c) 2012 Клінічна ендокринологія та ендокринна хірургія
Ця робота ліцензується відповідно до Creative Commons Attribution-NonCommercial 4.0 International License.
